The Division of Hematopathology combines the diagnostic aspects of laboratory hematology and coagulation, bone marrow, and hematolymphoid tissue interpretation and flow cytometric analysis. The overall Division of Hematopathology is directed by Dr. Gerard Lozanski who also directs the hematopathology fellowship program. Members of the division include Drs. Amy Gewirtz, Fredrick Racke, Arwa Shana’ah, Hafeng Wu, and Weiqiang Zhao. The coagulation laboratory is under the direction of Dr. Haifeng Wu, the flow cytometry laboratory under the direction of Dr. Lozanski, Dr. Racke assists in the operations and sign out of the cytogenetic laboratory and the hematology laboratory is under the director of Dr. Gewirtz. Dr. Zhao, is involved in development of clinical and research molecular testing as part of the Pathology Core Facility Laboratory.
In addition to their clinical duties the hematopathology division is actively involved in research projects and supports clinical studies through collaboration with oncologists, computer scientists and various cooperative research groups including CALGB, ECOG and TGCA and multiple Biopharm companies. .
In collaboration with Dr. Rolf Barth in the Department of Pathology and Dr. Nilendu Gupta in the Department of Radiation Medicine, Dr. Racke he has developed a novel therapy for the treatment of thrombocytopenia that has show significant efficacy in a murine model of radiation-induced bone marrow suppression. This therapy relies upon a unique pharmacologic strategy to influence erythromegakaryocytic differentiation and has therapeutic potential to translate into a novel therapy for patients with thrombocytopenia. He continues to lead the pathology leukemia cadre of the CALGB, participating in correlative science related to the refinement of the diagnosis of leukemia and development of clinical assays for prognostic markers in acute myeloid leukemia.
Dr. Wu’s laboratory is involved in basic research to understand the molecular pathways that underlie disease processes. Two diseases are presently under study, thrombotic thrombocytopenic purpura (TTP) and chronic obstructive pulmonary disorder (COPD). In TTP, a serious thrombotic disorder characterized by disseminated platelet thrombosis and subsequent severe tissue organ injury the laboratory is pursuing both transgenic (and knockout) mouse models and biochemical approaches to study host factors and underlying mechanisms that trigger the clinical phenotype of TTP. The laboratory is also involved in translational research to develop and implement novel biomarkers and treatment strategies to improve patient care. Dr. Wu also directs the Biomarker Reference Laboratory (BRL), part of clinical laboratory services at Ohio State University Medical Center (OSUMC). The BRL is actively engaged in OSU’s strategic mission in personalized health care. So far, the BRL has implemented 4 clinical tests derived from our research and innovation: ADAMTS13 activity assay; Determination of ADAMTS13 inhibitor titer; Genotyping for warfarin sensitivity SNPs; and von Willebrand factor (VWF) multimeric analysis.
Dr. Shana’ahcollaborates with Dr. Metin Gurcan t from the Department of Bioinformatics in the area of computer based image analysis algorithm for accurate histological grading of follicular lymphomas. Dr. Shana’ah is a participant in The Cancer Genome Atlas (TCGA) project sponsored by National Institute of Health.
Dr. Zhao directs the molecular pathology core facility laboratory at Polaris. Under his directorship molecular core laboratory developed and validated numerous clinical molecular and FISH tests that are used in daily clinical sign out as well as well as are used to support multiple clinical studies in different types of malignancies ranging from acute leukemia to breast cancer. Dr. Zhao expertise in development and analysis of molecular tests is valued by researchers at OSUMC, other institutions and cooperative groups and is supported by numerous collaborative grants. Dr. Zhao also helps with development of computer based image analysis for grading of follicular lymphoma and cutaneous T cell lymphoma. In addition Dr. Zhao is an active leukemia cadre member in CALGB and TCGA projects.
The Flow Cytometry Laboratory, under the direction of Dr. Gerard Lozanski, continues to experience marked increase in both of clinical and research specimens. The laboratory has expanded its detection of minimal residual disease to include not only CLL but also ALL and some types of T cell non Hodgkin lymphomas. Over the last several years laboratory developed and validated flow battery that allows detailed evaluation of the cellular immune status (IMMUNOME) of patients treated with hematological malignancies, HIV or and autoimmune disorders that are treated with various modalities including stem cell transplant, immunotherapy and immunomodulating drugs. In addition flow laboratory also developed expertise in quantitative measurement of density of surface antigens that are targets of immunotherapeutic agents treated with humanized monoclonal antibodies. Most recently the flow laboratory started to evaluate flow cytometric method to quantitatively measure the average length of telomeres by fluorescence in situ hybridization (FISH) method. Dr. Lozanski in collaboration with Dr. M. Gurcan from the Department of Bioinformatics has received an NIH grant for development of a computer program for accurate and reproducible histological grading of follicular lymphoma based on whole slide image analysis, placing our division in a unique leadership position in the rapidly emerging field of digital pathology.